Study of potential xanthine oxidase inhibitors: In silico and in vitro biological activity

  • Muthuswamy Umamaheswari Department of Pharmacology, College of Pharmacy, Sri Ramakrishna Institute of Paramedical Sciences, Coimbatore 641044, Tamil Nadu
  • Arumugam Madeswaran Department of Pharmacology, College of Pharmacy, Sri Ramakrishna Institute of Paramedical Sciences, Coimbatore 641044, Tamil Nadu
  • Kuppusamy Asokkumar Department of Pharmacology, College of Pharmacy, Sri Ramakrishna Institute of Paramedical Sciences, Coimbatore 641044, Tamil Nadu
  • Thirumalaisamy Sivashanmugam Department of Pharmacology, College of Pharmacy, Sri Ramakrishna Institute of Paramedical Sciences, Coimbatore 641044, Tamil Nadu
  • Varadharajan Subhadradevi Department of Pharmacology, College of Pharmacy, Sri Ramakrishna Institute of Paramedical Sciences, Coimbatore 641044, Tamil Nadu
  • Puliyath Jagannath Department of Pharmacology, College of Pharmacy, Sri Ramakrishna Institute of Paramedical Sciences, Coimbatore 641044, Tamil Nadu
Keywords: Allopurinol, AutoDock 4.2, Docking, Enzyme kinetics, Xanthine oxidase

Abstract

In an attempt to develop potent anti gout agents, coumarin derivatives and polyphenolic compounds were selected for present study. The docking energy of 2-benzyl coumarin was found to be -7.50 kcal/mol which was less than that of the standard allopurinol (-4.47 kcal/mol). All the selected compounds were found to exhibit lower binding energy (-7.50 to -4.68 kcal/mol) than allopurinol. Docking results confirm that selected compounds showed greater inhibition of xanthine oxidase due to their active binding sites. In xanthine oxidase assay, IC50 value of 2-benzyl coumarin was found to be 26 ± 1.16 µg/mL, whereas that of allopurinol was 24 ± 0.28 µg/mL. All the compounds exhibited IC50 values ranging between 26 ± 1.16 to 58 ± 0.74 µg/mL.  In enzyme kinetic studies, coumarin derivatives showed competitive and polyphenolic compounds showed non competitive type of enzyme inhibition. It can be concluded that coumarin derivatives could be a remedy for the treatment of gout and related inflammatory disorders.

Downloads

Download data is not yet available.
Abstract
2098
Download
1405 Read
460

Author Biographies

Muthuswamy Umamaheswari, Department of Pharmacology, College of Pharmacy, Sri Ramakrishna Institute of Paramedical Sciences, Coimbatore 641044, Tamil Nadu
Professor and HOD
Arumugam Madeswaran, Department of Pharmacology, College of Pharmacy, Sri Ramakrishna Institute of Paramedical Sciences, Coimbatore 641044, Tamil Nadu

Lecturer

Kuppusamy Asokkumar, Department of Pharmacology, College of Pharmacy, Sri Ramakrishna Institute of Paramedical Sciences, Coimbatore 641044, Tamil Nadu
Professor
Thirumalaisamy Sivashanmugam, Department of Pharmacology, College of Pharmacy, Sri Ramakrishna Institute of Paramedical Sciences, Coimbatore 641044, Tamil Nadu
Lecturer
Varadharajan Subhadradevi, Department of Pharmacology, College of Pharmacy, Sri Ramakrishna Institute of Paramedical Sciences, Coimbatore 641044, Tamil Nadu
Lecturer
Puliyath Jagannath, Department of Pharmacology, College of Pharmacy, Sri Ramakrishna Institute of Paramedical Sciences, Coimbatore 641044, Tamil Nadu
Lecturer

References

Azam F, Prasad MVV, Thangavel N. Molecular docking studies of 1-(substituted phenyl)-3-(naphtha [1,2d] thiazol -2-yl) urea/thiourea derivatives with human adenosine A2A receptor. Bioinformation. 2011; 6: 330-34.

Borges F, Feranandes E, Roleira F. Progress towards the discovery of xanthine oxidase inhibitors. Curr Med Chem. 2002; 9: 195-217.

Breda A, Basso LA, Santos DS, de Azevedo Jr WF. Virtual screening of drugs: Score functions, docking, and drug design. Curr Computer-Aided Drug Design 2008; 4: 265-72.

Cavasotto CN, Abagyan RA. Protein flexibility in ligand docking and virtual screening to protein kinases. J Mol Biol. 2004; 12: 209-25.

Chang MW, Ayeni C, Breuer S. Virtual screening for HIV protease inhibitors: A comparison of AutoDock 4 and vina. PLoS ONE. 2010; 5: 119-55.

Goodsell DS, Morris GM, Olson AJ. Automated docking of flexible ligands: Applications of Autodock. J Mol Recog. 1996; 9: 1-5.

Hediger AM. Molecular physiology of urate transport. Physiology 2005; 20: 125-33.

Khodade P, Prabhu R, Chandra N. Parallel implementation of Autodock. J App Crystal. 2007; 40: 598-99.

Kimura Y, Ito H, Ohnishi R, Hatano T. Inhibitory effects of polyphenols on human cytochrome P450 3A4 and 2C9 activity. Food Chem Toxicol. 2010; 48: 429-35.

Konc J, Konc JT, Penca M, Janezic M. Binding-sites prediction assisting protein-protein docking. Acta Chim Slov. 2011; 58: 396401.

Morris G, Goodsell D, Halliday R. Automated docking using Lamarckian genetic algorithm and an empirical binding free energy function. J Comp Chem. 1998; 19: 1639-62.

Niu Y, Zhu H, Liu J, Fan H, Sun L, Lu W, Liu X, Li L. 3,5,2',4'-Tetrahydroxychalcone, a new non-purine xanthine oxidase inhibitor. Chem Biol Inter. 2011; 189: 161-66.

Pacher P, Mabley GJ, Soriano GF, Liaudet L, Komjati K, Szabo C. Endothelial dysfunction in aging animals: The role of poly(ADP-ribose) polymerase activation. Br J Pharmacol. 2002; 135: 1347-50.

Pacher P, Nivorozhkin A, Szabo C. Therapeutic effect of xanthine oxidase inhibitors: Renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006; 58: 87-114.

Park H, Lee J, Lee S. Critical assessment of the automated AutoDock as a new docking tool for virtual screening. Proteins 2006; 65: 549-54.

Symons CRM, Taiwo AF, Petersen LR. Electron addition to xanthine oxidase. An electron spins resonance study of the effects of ionizing radiation. J Chem Soc. 1989; 85: 4063-74.

Umamaheswari M, Asokkumar K, Sivashanmugam AT, Remyaraju A, Subhadradevi V, Ravi TK. In vitro xanthine oxidase inhibitory activity of the fractions of Erythrina stricta Roxb. J Ethnopharmacol. 2009; 124: 646-48.

Umamaheswari M, Chatterjee TK. Hypouricemic and xanthine oxidase inhibitory activities of the fractions of Coccinia grandis L.Voigt. OPEM. 2008; 7: 477-84.

Umamaheswari M, Madeswaran A, Asokkumar K, Sivashanmugam AT, Subhadradevi V, Jagannath V. Docking studies: Search for possible phytoconstituents for the treatment of gout. Int J Biol Pharm Res. 2012; 3: 6-11.

Umamaheswari M, Madeswaran A, Asokkumar K, Sivashanmugam T, Subhadradevi V, Jagannath P. Discovery of potential xanthine oxidase inhibitors using in silico docking studies. Der Pharma Chemica. 2011; 3: 240-47.

Unno T, Sugimoto A, Kakuda T. Xanthine oxidase inhibitors from the leaves of Lagerstroemia species (L.) Pers. J Ethnopharmacol. 2004; 93: 391-95.

Werns SW, Grum CM, Ventura A, Hahn RA, Ho PP, Towner RD, Fantone JC, Schork MA, Lucchesi BR. Xanthine oxidase inhibition does not limit canine infarct size. Circulation 1991; 83: 995-1005.

Zhang S, Kumar K, Jiang X. DOVIS: An implementation for high throughput virtual ening using Autodock. BMC Bioinformatics. 2008; 9: 126-28.

Published
2011-12-17
How to Cite
Umamaheswari, M., A. Madeswaran, K. Asokkumar, T. Sivashanmugam, V. Subhadradevi, and P. Jagannath. “Study of Potential Xanthine Oxidase Inhibitors: In Silico and in Vitro Biological Activity”. Bangladesh Journal of Pharmacology, Vol. 6, no. 2, Dec. 2011, pp. 117-23, doi:10.3329/bjp.v6i2.9175.
Section
Research Articles